Use and attention to M.P.
I. Usage (i) Multi-mixer B 1. Immulcular dripping 1.5 – 2.5 mg/kg per day (generally not more than 2.5 mg/kg) for adults and children with normal kidney function, two times. Every 50 mg multimactin B should be injected with 5% glucose fluid 500ml and slowly dripping (no less than 120 minutes). For patients with reduced kidney function, the dose needs to be adjusted to the kidney function. 2. Injection (used in green sepsis) 5 mg per adult, 2 mg per child (under 2 years of age) and 3 mg per year (over 2 years of age) 3 – 4 days per day 1 time, usually requiring a slow injection after diluting to 5ml with physicosaline. 1. Orally administered adults in 5 – 1 million units, 3 – 4 times a day. The child dosage is based on body weight in 25 – 500,000 units/kg, 3 – 4 times a day, mainly for intestinal infections or pre-intestinal preparation. 2. Injection in myoline 100 – 1.5 million units per day for adults, 2 – 3 times. Children weigh 2 – 3 times a day in 2 – 3 million units/kg. 3. Vigilante drops 5-1 million units per day for adults, 2 times. Children weigh 15 – 25 million units/kg per day, 2 times. For intravenous drops, a suitable 5 per cent of glucose injection fluid or physio-saline water can be used after diluting, with a slower rate of dripping.
1. Renal toxicity The most significant adverse effects of a drug of polymixin are renal toxicity, which can be seen in protein urine, blood urine, tube urine, nitrogen haematosis, etc. The kidney function needs to be closely monitored during the use of the drug, in particular for patients with impairment of their own kidney function, as well as for patients with long-term or high-dose use. In the event of an abnormal kidney function, the dose may need to be adjusted or stopped. 2. Neural toxicity can be associated with neurotic symptoms such as dizziness, dizziness, numbing of the face, neurological inflammation in the surrounding area, hysteria, twitch, etc., in serious cases. In case of neurotoxicity, the continued use should be assessed in a timely manner. 3. Allergies are also likely to occur, and occasionally have been reported as a result of a sensitization shock. In case of skin itching, red spots, etc. during the course of the medication, be alert to allergies. 1. The risk of kidney damage will increase significantly and should be avoided to the extent possible when it is used with other renal toxicity drugs, such as polymixin and other renal toxicity substances, such as aminocin. If shared, the kidney function needs to be closely monitored. 2. Muscle laxants enhance the function of muscle laxants and may lead to respiratory inhibition or suspension of breathing when shared, with particular caution in their use and, where required, close monitoring of the respiratory function. 1. Medicines of multi-mixerella-types for pregnant and lactating women can be accessed through placental barriers or in small quantities, which may have adverse effects on the foetus or the infant, and use by pregnant and lactating women needs to be weighed against the potential benefits that may be greater than the potential risks to the foetus or the baby. 2. Children need to be measured accurately on the basis of body weight when using PMC-type drugs, while paying close attention to adverse reactions, in particular the possible developmental effects of renal and neurotoxicity on children. 3. Older persons The kidney function of older persons is often reduced to varying degrees, and adverse effects, such as renal toxicity, are more likely to occur with the use of PMOs, which should be carefully adjusted and monitoring of kidney function and other adverse effects strengthened. (iv) Use Note 1. Before the use of a polymixer-type drug, the patient ‘ s allergy history should be asked in detail and the polymixer is banned. 2. Due to the high renal and neurotoxicity of PMC-type drugs, adaptive certificates are strictly used to avoid unnecessary long-term or large-dose use. At the same time, intravenous drips are subject to strict control of drip speed and drug concentrations to reduce the occurrence of adverse reactions. In the event of any discomfort during the course of the medication, medical treatment should be assessed and treated in a timely manner.
